Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Tourmaline Bio in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($2.91) per share for the year. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share.

Several other equities analysts have also recently weighed in on TRML. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Chardan Capital reaffirmed a “buy” rating and set a $70.00 price objective on shares of Tourmaline Bio in a research report on Monday, May 5th. Lifesci Capital started coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They set an “outperform” rating and a $58.00 price objective for the company. Finally, Wedbush upped their price objective on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Tourmaline Bio currently has an average rating of “Buy” and an average target price of $49.33.

Tourmaline Bio Stock Performance

Shares of TRML stock opened at $19.90 on Wednesday. The company has a market capitalization of $511.13 million, a P/E ratio of -7.06 and a beta of 2.05. Tourmaline Bio has a 52 week low of $11.56 and a 52 week high of $29.79. The company’s 50 day moving average price is $16.08 and its two-hundred day moving average price is $17.25.

Tourmaline Bio (NASDAQ:TRML) last released its earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.02.

Institutional Trading of Tourmaline Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. QVT Financial LP increased its position in Tourmaline Bio by 107.1% during the 1st quarter. QVT Financial LP now owns 1,473,369 shares of the company’s stock valued at $22,410,000 after purchasing an additional 762,094 shares during the period. Vanguard Group Inc. increased its stake in shares of Tourmaline Bio by 7.7% in the 1st quarter. Vanguard Group Inc. now owns 1,190,810 shares of the company’s stock valued at $18,112,000 after acquiring an additional 84,685 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in shares of Tourmaline Bio in the 1st quarter valued at $13,765,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Tourmaline Bio in the 4th quarter valued at $12,168,000. Finally, Velan Capital Investment Management LP increased its stake in shares of Tourmaline Bio by 7.5% in the 1st quarter. Velan Capital Investment Management LP now owns 455,412 shares of the company’s stock valued at $6,927,000 after acquiring an additional 31,617 shares in the last quarter. Institutional investors and hedge funds own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.